Latest Affymetrix Microarray Offers New Users a Cost-effective and Easy-to-use Alternative for Gene-level Expression Profiling.Human Gene 1.0 ST Array delivers a more complete and accurate view for well-known genes compared to traditional 3' microarrays SANTA CLARA Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. , Calif. -- Affymetrix Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AFFX) today announced the full commercial launch of the GeneChip([R]) Human Gene 1.0 ST Array, the latest addition to its whole-transcript assay-based gene expression product family. The new microarray measures the overall expression of all transcripts derived from a gene, not just the 3' end of a gene. As a result, the Human Gene 1.0 ST Array delivers a more complete and accurate view of a gene's total transcription activity compared to traditional expression array designs. The Human Gene 1.0 ST Array is a cost-effective gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, option for new microarray users. Its affordable price and simplified workflow will enable more scientists to incorporate microarray technology in their research more often. Researchers will also be able to perform larger expression studies with additional replicates to gain a more accurate picture of gene activity. The latest Affymetrix product complements the more comprehensive Human Exon Exon In split genes, a portion that is included in the ribonucleic acid (RNA) transcript of a gene and survives processing of the RNA in the cell nucleus to become part of a spliced messenger RNA (mRNA) or structural RNA in the cell cytoplasm. 1.0 ST Array, which offers both gene-level expression profiling and alternative splicing Alternative splicing is the RNA splicing variation mechanism in which the exons of the primary gene transcript, the pre-mRNA, are separated and reconnected so as to produce alternative ribonucleotide arrangements. analysis in a single experiment. "The new Human Gene 1.0 ST Array offers the latest available content at an attractive price point, making it an ideal solution for researchers with restricted budgets who were not able to work with Affymetrix technology in the past," said Shawn Levy Shawn Adam Levy (born 1967) is a Canadian American director and actor. He was born in Montreal, Quebec. Levy is the director of Big Fat Liar, Just Married, Cheaper by the Dozen, The Pink Panther, and Night at the Museum. , Ph.D., assistant professor of biomedical informatics Biomedical informatics is a term used to describe the broad discipline that encompasses such subdomains as bioinformatics, clinical informatics, public health informatics, etc, and is most commonly used in this way in the USA[1]. and director of the Vanderbilt Microarray Shared Resource Sharing a peripheral device (disk, printer, etc.) among several users. For example, a file server and laser printer in a LAN are shared resources. Contrast with shared logic. . "With the gene and exon arrays on the same WT assay platform, Affymetrix provides a logical product progression that enables customers to gain an understanding of the critical roles that gene expression or alternative splicing play in biology." In the Human Gene 1.0 ST Array design, each of the 28,869 genes is represented by a set of approximately 26 probes. This simplified design strategy provides one value from one probe set for each gene, yielding a more accurate representation of all of the transcription activities for each gene of interest than traditional expression array designs. Affymetrix Expression Console[TM] Software offers additional tools to further simplify the analysis workflow, making it as easy to interpret gene-level expression on Human Gene 1.0 ST Arrays as 3'-based expression microarrays. "Between the traditional 3' U133 Array, the new-generation Human Exon 1.0 ST Array and now the Human Gene 1.0 ST Array, Affymetrix has the most complete portfolio of gene expression products to meet the growing and diverging di·verge v. di·verged, di·verg·ing, di·verg·es v.intr. 1. To go or extend in different directions from a common point; branch out. 2. To differ, as in opinion or manner. 3. customer demands," said Sean George, vice president of the academic business unit at Affymetrix. "The new Human Gene 1.0 ST Array complements the Human Exon 1.0 ST Array, offering an additional choice for new microarray users on the gold-standard microarray platform at a very affordable price. This product is a direct result of Affymetrix' continued innovation and dedication to making larger-scale genomic studies more economical." The Affymetrix Human Gene 1.0 ST Array utilizes the same GeneChip technology that has been the industry standard in microarray research for the past decade. More than 1,500 systems have been shipped around the world and the technology has generated data for more than 8,500 peer-reviewed scientific publications. The complete system includes flexible instrumentation, proven GeneChip microarrays, optimized assays and reagents, as well as open software architecture. For more information on recent discoveries using Affymetrix whole-transcript gene expression products, please visit: Researchers Discover Expression Profiles with Distinct Splice Variants that Improves Glial Tumor glial tumor Neurology A 1º CNS tumor arising in neurons and neural processes. See Brain tumor. Classification http://www.microarraybulletin.com/community/article.php?p=226 Researchers Investigate Variation in Alternative Splicing in a Human Population http://microarraybulletin.com/community/article.php?p=257 Gene Expression Analysis on Exon Arrays Provides High-sensitivity Results http://www.microarraybulletin.com/community/article.php?p=258 Gene Expression Summaries and Detection of Alternative Splicing http://www.microarraybulletin.com/community/article.php?p=256 For more information on the Affymetrix Human Gene 1.0 ST Array, please visit: http://www.affymetrix.com/genechip/genearray.affx. About Affymetrix Affymetrix GeneChip([R])microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. , as well as leading academic, government and not-for-profit research institutes. More than 1,500 systems have been shipped around the world and more than 8,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. Forward-looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the success of the Affymetrix Human Gene 1.0 ST Array discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. ; uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other risk factors are discussed in Affymetrix' Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip([R]) are registered trademarks owned or used by Affymetrix Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion